Korro Bio doses first cohort in Phase 1/2 ANCHOR trial of KRRO-121 for urea cycle disorders

Korro Bio, Inc.

First cohort of healthy volunteers received a single 2mg/kg dose of KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide (REO) targeting hyperammonemia in UCD and hepatic encephalopathy.
ANCHOR Part 1: placebo-controlled SAD in up to 30 healthy volunteers across up to 5 cohorts, then MAD in up to 20 subjects across 2 cohorts; enrollment is in Australia (NCT07773246).
ANCHOR Part 2: Phase 2 multiple-dose study in up to 15 UCD patients across all UCD genotypes, subject to regulatory approval.
Dosing in UCD patients expected to begin in the first half of 2027, with an interim readout expected in the second half of 2027.
CEO Ram Aiyar said KRRO-121 blunted ammonia excursions in multiple preclinical studies across different mutations; trial first aims to establish safety, then activity.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.